Clinical Report: Alopecia therapy gains FDA breakthrough status

Overview

The FDA granted Breakthrough Therapy Designation to CINAINU (LH-8), an investigational cutaneous botanical solution for moderate-to-severe alopecia areata in patients aged 2 years and older. The designation was supported by the phase 2/3 RAAINBOW trial, but the company announcement provided no numerical efficacy or safety results. The designation is not FDA approval; Legacy Healthcare is preparing a global pivotal phase 3 program.

Background

Alopecia areata is treated with FDA-approved oral Janus kinase (JAK) inhibitors for certain patients with severe disease. The source reports that these approvals are limited to adults and adolescents, leaving children and people with moderate disease without approved treatment options. It also notes boxed warnings for serious risks, including infections, malignancy, cardiovascular events, and thrombosis. LH-8 is being investigated across age groups and disease severity, including as possible continuation therapy after oral JAK inhibitor treatment.

Data Highlights

Key Findings

• The FDA granted Breakthrough Therapy Designation to CINAINU (LH-8) for moderate-to-severe alopecia areata in patients aged 2 years and older, according to Legacy Healthcare.
• The designation was supported by the phase 2/3 RAAINBOW trial, which enrolled 107 participants aged 2 to 17 years and used a randomized, double-blind, placebo-controlled design.
• Legacy Healthcare reported meaningful hair regrowth, favorable tolerability, and sustained benefits, but did not provide numerical efficacy results, adverse event rates, or the duration of benefit.
• Breakthrough Therapy Designation is intended to accelerate development and review of investigational treatments with preliminary evidence of substantial improvement over available therapies; it does not constitute FDA approval.
• The source describes approved oral JAK inhibitor options as limited to adults and adolescents with severe alopecia areata and notes boxed warnings for serious safety risks, including infections, malignancy, cardiovascular events, and thrombosis.
• Legacy Healthcare is preparing a global pivotal phase 3 program in adults, adolescents, and children and is investigating LH-8 for moderate or severe disease and as possible continuation therapy after oral JAK inhibitor treatment.

Clinical Implications

LH-8 remains investigational and should not be considered an FDA-approved treatment on the basis of this designation. The available announcement does not provide numerical trial outcomes or detailed safety data, so those results cannot be assessed from the reported information.

Conclusion

The designation advances development of LH-8 for alopecia areata across age groups, while its efficacy and safety remain to be established through further clinical evaluation. Legacy Healthcare is preparing a global pivotal phase 3 program.

Related Resources & Content

1. Legacy Healthcare, PR Newswire, Year not stated — Legacy Healthcare's CINAINU® Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older
2. US Food and Drug Administration, 2022 — FDA Approves First Systemic Treatment for Alopecia Areata
3. The ASCO Post — FDA Grants Breakthrough Therapy Designation for First-Line Treatment of ALK-Positive NSCLC
4. The ASCO Post — FDA Clears Expanded Indication of Scalp-Cooling System
5. The ASCO Post — FDA Clears Expanded Indication of Scalp-Cooling System
6. The ASCO Post — FDA Grants Breakthrough Therapy Status to Entinostat for Advanced Breast Cancer Key Points
7. Legacy Healthcare's CINAINU® Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older
8. FDA Approves First Systemic Treatment for Alopecia Areata
9. FDA Approves First Systemic Treatment for Alopecia Areata
10. Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults | Dermatology | JAMA Dermatology | JAMA Network
11. Two Phase 3 Trials of Baricitinib for Alopecia Areata | New England Journal of Medicine